EKG

Object Management Group Acquires Enterprise Knowledge Graph Foundation

Retrieved on: 
Thursday, February 29, 2024

BOSTON, MA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, Object Management Group ®️ (OMG®️) announced it has acquired the Enterprise Knowledge Graph Foundation (EKGF).

Key Points: 
  • BOSTON, MA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, Object Management Group ®️ (OMG®️) announced it has acquired the Enterprise Knowledge Graph Foundation (EKGF).
  • A non-profit trade association founded in 2020 by leading industry experts in the knowledge graph space, EKGF develops a catalog of best practices for sustainable knowledge graph deployment in an enterprise.
  • A knowledge graph is a collection of descriptions that put data in context through links and semantic metadata.
  • Today OMG also announced the Enterprise Knowledge Graph Forum (EKGF) Community .

Casino Industry Experts Honor Aristocrat Gaming™ with "Best Overall Supplier" at EKG Slot Awards

Retrieved on: 
Friday, March 1, 2024

LAS VEGAS, March 1, 2024 /PRNewswire/ -- Last night, Aristocrat Gaming was awarded "Best Overall Supplier of Slot Content" for the sixth consecutive year at the annual EKG Slot Awards.

Key Points: 
  • LAS VEGAS, March 1, 2024 /PRNewswire/ -- Last night, Aristocrat Gaming was awarded "Best Overall Supplier of Slot Content" for the sixth consecutive year at the annual EKG Slot Awards.
  • The company also earned multiple other distinctions, including:
    "We are honored to have been recognized at this year's awards and it is something we do not take for granted," said Hector Fernandez, CEO of Aristocrat Gaming.
  • The EKG Slot Awards are produced by Eilers & Krejcik Gaming (EKG) and recognize excellence in slot game development in the casino gaming industry.
  • For more information about any of Aristocrat's industry-leading and award-winning games, cabinets, and system solutions, contact your Aristocrat representative or visit aristocratgaming.com .

Ontotext Enhances the Performance of LLMs and Downstream Analytics with Latest Version of Ontotext Metadata Studio

Retrieved on: 
Thursday, February 22, 2024

NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Ontotext, the leading global provider of enterprise knowledge graph (EKG) technology and semantic database engines, today announced the immediate availability of Ontotext Metadata Studio (OMDS) 3.7, an all-in-one environment that facilitates the creation, evaluation, and quality improvement of text analytics services. This latest release provides out-of-the-box, rapid natural language processing (NLP) prototyping and development so organizations can iteratively create a text analytics service that best serves their domain knowledge.

Key Points: 
  • This latest release provides out-of-the-box, rapid natural language processing (NLP) prototyping and development so organizations can iteratively create a text analytics service that best serves their domain knowledge.
  • "Ontotext Metadata Studio addresses this by enabling organizations to utilize state of the art information extraction so they can make their own content discoverable through the worlds biggest public knowledge graph dataset."
  • Enrich content, achieve precise search, improve SEO, and enhance the performance of LLMs and downstream analytics.
  • This latest offering further allows users to perform entity linking against their own taxonomies and reference data.

Ontotext Enhances the Performance of LLMs and Downstream Analytics with Latest Version of Ontotext Metadata Studio

Retrieved on: 
Thursday, February 22, 2024

NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Ontotext, the leading global provider of enterprise knowledge graph (EKG) technology and semantic database engines, today announced the immediate availability of Ontotext Metadata Studio (OMDS) 3.7, an all-in-one environment that facilitates the creation, evaluation, and quality improvement of text analytics services. This latest release provides out-of-the-box, rapid natural language processing (NLP) prototyping and development so organizations can iteratively create a text analytics service that best serves their domain knowledge.

Key Points: 
  • This latest release provides out-of-the-box, rapid natural language processing (NLP) prototyping and development so organizations can iteratively create a text analytics service that best serves their domain knowledge.
  • "Ontotext Metadata Studio addresses this by enabling organizations to utilize state of the art information extraction so they can make their own content discoverable through the worlds biggest public knowledge graph dataset."
  • Enrich content, achieve precise search, improve SEO, and enhance the performance of LLMs and downstream analytics.
  • This latest offering further allows users to perform entity linking against their own taxonomies and reference data.

X-trodes Receives FDA 510(k) Clearance for Wearable "Skin" Solution that Brings Medical-Grade Electrophysiological Monitoring to the Home

Retrieved on: 
Tuesday, February 20, 2024

HERZLIYA, Israel, Feb. 20, 2024 /PRNewswire/ -- X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M), a new wireless wearable technology for advanced electrophysiological monitoring.  

Key Points: 
  • The discreet patches are easy to apply and comfortable to wear, conforming to the body without requiring gels, wires or uncomfortable solutions.
  • The FDA clearance follows successful completion of an extensive scientific assessment that evaluated the accuracy and consistency of X-trodes' system.
  • "Gaining FDA clearance affirms the value of this technology and its potential to improve health and wellness through access to real-time electrophysiological data.
  • Electrophysiological monitoring has traditionally been restricted to clinics, requiring cumbersome hardware and controlled environments to acquire highly sensitive physiological signals.

X-trodes Receives FDA 510(k) Clearance for Wearable "Skin" Solution that Brings Medical-Grade Electrophysiological Monitoring to the Home

Retrieved on: 
Tuesday, February 20, 2024

HERZLIYA, Israel, Feb. 20, 2024 /PRNewswire/ -- X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M), a new wireless wearable technology for advanced electrophysiological monitoring.  

Key Points: 
  • The discreet patches are easy to apply and comfortable to wear, conforming to the body without requiring gels, wires or uncomfortable solutions.
  • The FDA clearance follows successful completion of an extensive scientific assessment that evaluated the accuracy and consistency of X-trodes' system.
  • "Gaining FDA clearance affirms the value of this technology and its potential to improve health and wellness through access to real-time electrophysiological data.
  • Electrophysiological monitoring has traditionally been restricted to clinics, requiring cumbersome hardware and controlled environments to acquire highly sensitive physiological signals.

PCA 500™-- the world's most efficient and versatile 12-lead ECG, receives FDA clearance for use in acute care

Retrieved on: 
Tuesday, February 13, 2024

PCA 500 was first 510(k) cleared in 2018 for professional and personal use by adults in non-acute care settings, including patient's homes.

Key Points: 
  • PCA 500 was first 510(k) cleared in 2018 for professional and personal use by adults in non-acute care settings, including patient's homes.
  • In 2022, QT Medical received 510(k) clearance of PCA 500 use in infants, children and adolescents.
  • The new FDA clearance expands PCA 500's indication for use to all healthcare settings, including: hospitals, intensive care units, emergency rooms and ambulances.
  • With the FDA clearance for use in acute care, such as ambulances and emergency rooms, PCA 500 brings significant values to where efficiency and accuracy are needed the most."

Best Life Insurance Plans for Diabetics - Our Top Picks for 2024

Retrieved on: 
Monday, February 12, 2024

Continued Bland, "Our 50-insurer database is continually updated, which makes it a valuable resource for diabetics who are searching for the best buys in life insurance."

Key Points: 
  • Continued Bland, "Our 50-insurer database is continually updated, which makes it a valuable resource for diabetics who are searching for the best buys in life insurance."
  • Instant life insurance quotes for both type 1 and type 2 diabetics are available at www.lifequotes.com .
  • Life insurance policies described, quoted, shown and illustrated throughout this press release may not be available in all states.
  • Pacific Life Insurance Company of Newport Beach, CA, policy form P16LYT or ICC 16 P16LYT.

RAJANT INTRODUCES DISTRIBUTED EDGE AI PLATFORM AT CES

Retrieved on: 
Monday, January 8, 2024

Known as the Cowbell, the edge AI platform is a distributed computing hub and platform-as-a-service to streamline and simplify the delivery and management of AI applications at the edge.

Key Points: 
  • Known as the Cowbell, the edge AI platform is a distributed computing hub and platform-as-a-service to streamline and simplify the delivery and management of AI applications at the edge.
  • The Cowbell platform simplifies this complex problem by providing software, hardware, and networking infrastructure necessary to bring distributed cloud native computing to the edge with what we’re calling MLOps-in-a-Box.
  • By leveraging Rajant’s patented InstaMesh® networking technology, the Cowbell platform facilitates a secure, fault-tolerant, highly available distributed computing cluster over mesh, the first of its kind.
  • Schedule a time to meet at CES or stop by Zeno 4610 within The Venetian to see the latest Rajant family of products.

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Retrieved on: 
Thursday, January 4, 2024

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • Ravi Anand, Newron’s Chief Medical Officer, said: “Treatment with evenamide as an add-on to antipsychotics in TRS patients has produced benefits that have never been reported before.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).